Clinical Trial Update: Study Evaluating Bifeprunox in Bipolar Depression [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Bifeprunox for bipolar depression has completed; sponsor Wyeth/Pfizer provided an update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Bifeprunox (bifeprunox)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Bipolar Disorder | Phase 3 | Status: COMPLETED